Innovations in treatment for drug abuse: Solutions to a public health problem

Annual Review of Public Health

Volumn 22, Issue , 2001, Pages 249-272

  Sindelar, Jody L ^a   Fiellin, David A ^b  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Treatment of illicit drug use

Indexed keywords

BUPRENORPHINE; ILLICIT DRUG; LEVACETYLMETHADOL; METHADONE; NALTREXONE;

COST EFFECTIVENESS ANALYSIS; CRIME; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; HEALTH CARE ACCESS; HEALTH PROGRAM; HUMAN; MOTIVATION; PATIENT COUNSELING; PRIMARY PREVENTION; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT PLANNING;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DRUG THERAPY; HUMANS; MOTIVATION; OPIOID-RELATED DISORDERS; PRISONERS; PSYCHOTHERAPY; PUBLIC HEALTH; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 0035007684     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.publhealth.22.1.249     Document Type: Review

References (116)

1. Alterman AI, O'Brien CP, McLellan AT, August DS, Snider EC, et al. 1994. Effectiveness and costs of inpatient versus day hospital cocaine rehabilitation. J. Nerv. Ment. Dis. 182(3):157-63
2. Anderson DW, Bowland BJ, Cartwright WS, Bassin G. 1998. Service-level costing of drug abuse treatment. J. Subst. Abuse Treat. 15(3):201-11
3. Anglin MD, Speckart GR, Booth MW, Ryan TM. 1989. Consequences and costs of shutting off methadone. Addict. Behav. 14:307-26
4. Avants SK, Margolin A, Sindelar JL, Rounsaville BJ, Schottenfeld R, et al. 1999. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. Am. J. Psychol. 156(1):27-33
5. Ball JC, Ross A. 1991. The Effectiveness of Methadone Maintenance Treatment. New York: Springer-Verlag
6. Barnett P, Swindle R. 1997. Cost-effectiveness of inpatient substance abuse treatment. Health Serv. Res. 32(5):615-29
7. Deleted in proof
8. Belenko S. 1998. Research on drug courts: a critical review. Natl. Drug Court Inst. Rev. 1(1):1-27
9. Bickel WK, Amass L. 1995. Buprenor- phine treatment of opioid dependence: a review. Exp. Clin. Psychopharmacol. 3:477- 89
10. Bickel WK, Amass L, Higgins ST, Badger GJ, Esch R. 1997. Behavioral treatment improves outcomes during opioid detoxification with buprenorphine. J. Consult. Clin. Psychol. 65:803-10
11. Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE. 1997. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch. Gen. Psychiatry 54(1):71-80
12. Bukoski WJ, Evans RI. 1998. Cost Effectiveness Research of Drug Abuse Prevention: Implications for Programming and Policy. Natl. Inst. Drug Abuse Res. Monogr. No. 176. Rockville, MD: Natl. Inst. Drug Abuse
13. Carroll KM. Methodological issues and problems in assessment of substance use. Psychol. Assess. 7:349-58
14. Cartwright WS. 1998. Cost-benefit and cost-effectiveness analysis of drug abuse treatment services. Eval. Rev. 22(5):609- 36
15. Cent. Addict. Subst. Abuse. 1998. Behind Bars: Substance Abuse and America's Prison Population. New York: Columbia Univ. Press
16. Chiang CN, Hollister LE, Gillespie HK, Foltz RL. 1985. Clinical evaluation of a naltrexone sustained-release preparation. Drug Alcohol Depend. 16(1):1-8
17. Cooper JR. 1992. Ineffective use of psychoactive drugs. Methadone treatment is no exception. JAMA 267:281-82
18. Cooper JR. 1995. Including narcotic addiction treatment in an office-based practice. JAMA 273(20):1619-20
19. Criminal Justice Fact Sheet, Office Natl. Drug Policy. 1998. www.whitehousedrug-policy.gov
20. D'Aunno T, Vaughn T. 1992. Variations in methadone treatment practices. JAMA 267:253-58
21. D'Aunno T, Vaughn T. 1995. An organizational analysis of service patterns in drug abuse treatment. J. Subst. Abuse 24:13-18
22. De Leon G, Ziegenfuss JT. 1986. Therapeutic Communities for Addictions: Readings in Theory, Research and Practice. Springfield, IL: Thomas
23. Dole VP. 1965. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 193:646-50
24. Dole VP, Nyswander ME, Kreek MJ. 1966. Narcotic blockade. Arch. Int. Med. 118:304-9
25. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. 1997. Methods for the Eco- nomic Evaluation of Health Care Pro- grams. Oxford, UK: Oxford Univ. Press. 2nd ed.
26. French MT, Bradley CJ, Calingaert B, Den- nis ML, Karuntzos GT. 2000. Cost analysis of training and employment services in methadone treatment. Eval. Progr. Plan. In press
27. French MT, Dunlap LJ, Zarkin GA, McGeary KA, McLellan AT. 1997. A Structured instrument for estimating the economic cost of drug abuse treatment: the Drug Abuse Treatment Cost Analysis Program (DATCAP). J. Subst. Abuse Treat. 14(4):1-11
28. French MT, Mausopf JE, Teague JL, Roland EJ. 1996. Estimating the dollar value of health outcomes from drug-abuse interventions. Med. Care 34(9):890-910
29. French MT, McCollister KA, Sacks S, McKendrick K, DeLeon G. 1999. Benefit Cost Analysis of Ancillary Social Services in Publicly Supported Addiction Treat- ment. Miami: Health Serv. Res. Cent., Univ. Miami, Miami
30. French MT, McGeary KA. 1997. Estimating the economic cost of substance abuse treatment. Health Econ. 6:539-44
31. French MT, Rachal JV, Hubbard RL. 1991. Conceptual framework for estimating the social cost of drug abuse. J. Health Soc. Pol. 2(3):1-22
32. French MT, Salome HJ, Sindelar JL, McLellan AT. 2000. Benefit-cost analy- sis of addiction treatment: methodological guidelines and empirical applications us- ing the DATCAP and ASI. PhD thesis. Univ. Miami, Coral Gables, FL. In press
33. Gerstein DR, Harwood HJ, ed. 1990. Treating Drug Problems, Vol. 1. Washington, DC: Natl. Acad. Press
34. Gerstein DR, Johnson RA, Harwood H, Fountain D, Sutter N, Malloy K. 1994. Evaluating Recovery Services. The California Drug and Alcohol Treatment Assessment (CALDATA). Sacramento, CA: State Calif., Dep. Drug Alcohol Progr.
35. Gold MR, Siegel JE, Russell LB, Weinstein MC, ed. 1996. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ. Press
36. Greenstein RA, O'Brien CP, McLellan AT, Woody GE, Grabowski J, et al. 1981. Naltrexone: a short-term treatment for opiate dependence. Am. J. Drug Alcohol Abuse 8:291-300
37. Griffith JD, Hiller ML, Knight K, Simpson DD. 1999. A cost-effectiveness analysis of in-prison therapeutic community treatment and risk classification. Prison J. 79(3):353-68
38. Gutzwiller F, Steffen T, eds. 2000. Cost-Benefit Analysis of Heroin Maintenance Treatment. New York: Karger
39. Harwood H, Fountain D, Livermore G. 1997. The economic costs of alcohol and drug abuse in the US, 1992. NIDA/NIAAA Sponsored Rep. Rockville, MD: Lewin Group
40. Harwood HJ, Hubbard RL, Collins J, Rachal JV. 1995. A cost-benefit analysis of drug abuse treatment. Res. Law Policy Stud. 3:191-214
41. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G. 1993. Achieving cocaine abstinence with a behavioral approach. Am. J. Psychol. 150:763-69
42. Higgins ST, Budney AJ, Bickel WK, Foerg FE, Donham R, Badger G. 1994. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch. Gen. Psychiatry 51(7):568-76
43. Higgins ST, Delaney DD, Budney AJ, Bickel WK, Hughes JR, et al. 1991. A behavioral approach to achieving initial cocaine abstinence. Am. J. Psychiatry 148(9):1218-24
44. Higgins ST, Stitzer ML, Bigelow GE, Liebson IA. 1986. Contingent methadone delivery: effects on illicit-opiate use. Drug Alcohol Depend. 17:311-22
45. Higgins ST, Wong CJ, Badger GJ, Haug Ogden DE, Dantona RL. 2000. Contin- gent reinforcement increases cocaine abstinence during outpatient treatment and one year follow-up. J. Consult. Clin. Psychol. 68:64-72
46. Hubbard RL, Craddock SG, Flynn PM, Patrick M, Anderson J, et al. 1997. Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol. Addict. Behav. 11(4):261-78
47. Hubbard RL, French MT. 1991. New perspectives on the benefit-cost and cost-effectiveness of drug abuse treatment. In Economic Costs, Cost-Effectiveness, Financing, and Community-Based Drug Treatment, Res. Monogr. No. 113, DHHS Publ. No. ADM 91-1823, ed. WS Cartwright, JM Kaple, pp. 94-113. Rockville, MD: Natl, Inst, Drug Abuse
48. Hubbard RL, Marsden ME, Rachat JV, Harwood HJ, Cavanaugh ER, Ginzburg HM. 1989. Drug abuse treatment: A National Study of Effectiveness. Chapel Hill: Univ. North Carolina Press
49. Hughley R, Klemke LW. 1996. Evaluation of a jail-based substance abuse treatment program. Fed. Probat. 60(4):40-44
50. Inciardi JA, Martin SS, Butzin CF, Hooper RM, Harrison LD. 1997. An effective model of prison-based treatment for drug involved offenders. J. Drug Issues 27(2):261-78
51. Johnson R, Jaffe J, Fudala P. 1992. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267:2750-55
52. Johnson R, Strain EC. 1999. Other medications for opioid dependence. In Methadone Treatment for Opioid Dependence, ed. EC Strain, ML Stitzer, pp. 281-321. Baltimore, MD; Johns Hopkins Univ. Press
53. Kenkel D. 1997. On valuing morbidity, cost-effectiveness analysis, and being rude. J. Health Econ. 16:749-57
54. Kosten T, Shottenfeld R, Ziedonis D, Falcioni J. 1993. Buprenoiphine versus methadone maintenance for opioid dependence. J. Nerv. Ment. Dis. 181:358-64
55. Kraft MK, Rothbard AB, Hadley TR, McLellan AT, Asch DA. 1997. Are supplementary services provided during methadone maintenance really cost-effective? Am. J. Psychol. 154(9):1214-19
56. Leukefeld CG, Tims F, eds. 1992. Drug Abuse Treatment in Prison and Jails. NIDA Res. Monogr. 188. Rockville, MD: Natl. Inst. Drug Abuse
57. Ling W, Charuvastra C, Kaim SC, Klett J. 1976. Methadyl acetate and methadone as maintenance treatments for heroin addicts. Arch. Gen. Psychiatry 33:709-20
58. Ling W, Compton P. 1997. Opiate maintenance therapy with LAAM. In New Treatments for Opiate Dependence, ed. SM Stine, TR Kosten, pp. 231-53. New York: Guilford. 286 pp.
59. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, et al. 1998. Buprenorphine maintenance treatment of opiate de- pendence: a multicenter, randomized clinical trial. Addiction 93(4):475-86
60. Ling W, Rawson RA, Compton MA. 1994. Substitution pharmacotherapies for opioid addition: from methadone to LAAM and buprenorphine. J. Psychoact. Drugs 26(2):119-28
61. Lynam DR, Milich R, Zimmerman R, Novak SP, Logan TK, et al. 1999. Project DARE: no effects at 10-year follow-up. J. Consult. Clin. Psychol. 67(4):590-93
62. Magura S, Rosenblum A, Lewis C, Joseph H. 1993. The effectiveness of in-jail methadone maintenance. J. Drug Issues 23(1):75-95
63. Mauser E, Van Stelle KR, Moberg DP. 1994. The economic impact of diverting substance-abusing offenders into treatment. Crime Delinq. 40:568-88
64. Deleted in proof
65. McGlothlin WH, Anglin MD. 1981. Shutting off methadone: costs and benefits. Arch. Gen. Psychiatry 38:885-92
66. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. 1993. The effects of psychosocial services in substance abuse treatment. JAMA 269(15):1953-59
67. McLellan AT, Grissom GR, Zanis D, Randall M, Brill P, O'Brien CP. 1997. Problem-service "matching" in addiction treatment: a prospective study in four programs. Arch. Gen. Psychiatry 54(8):730-35
68. McLellan AT, Hagan TA, Meyers K, Levine M, Gould F, et al. 1998. Supplemental social services improve outcomes in public addiction treatment. Addiction 93(10):1489-99
69. McLellan AT, Hagan TA, Levine M, Meyers K, Randall M, et al. 1999. Does clinical case management improve outpatient addiction treatment? Drug Alcohol Depend. 55(1-2):91-103
70. McLellan AT, Luborsky L, Woody GE, O'Brien CP, Druley KA. 1983. Increased effectiveness of substance abuse treatment: a prospective study of patient-treatment "matching." J. Nerv. Ment. Dis. 17(10):597-605
71. McLellan AT, O'Brien CP, Luborsky L, Woody GE, Kron R. 1981. Are the addiction-related problems of substance abusers really related? J. Nerv. Ment. Dis. 169(4):232-39
72. McLellan AT, Weisner C. 1996. Achieving the public health potential of substance abuse treatment: implications for patient referral, treatment "matching," and outcome evaluation. In Drug Policy and Human Nature: Psychological Perspectives on the Prevention, Management, and Treatment of Illicit Drug Abuse, ed. WK Bickel, RJ DeGrandpre. New York: Plenum
73. Mello NK, Mendelson JH, Kuehnle JC, Sellers MS. 1981. Operant analysis of human heroin self-administration and the effects of naltrexone. J. Pharmacol. Exp. Ther. 216:45-54
74. Natl. Consens. Dev. Panel Effect. Med. Treat. Opiate Addict. 1998. Effective medical treatment of opiate addiction. JAMA 280:1936-43
75. NIDA Infofa76. 1997. Treatment trends. www.nida.nih.gov/Infofax/treatment-trends.html
76. Novick DM, Joseph H, Salsitz EA, Kalin MF, Keefe JB, et al. 1994. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): follow-up at three and a half to nine and a fourth years. J. Gen. Intern. Med. 9(3):127-30
77. Novick DM, Pascarelli EF, Joseph H, Salsitz EA, Richman BL, et al. 1988. Methadone maintenance patients in general medical practice: a preliminary report. JAMA 259:3299-302
78. O'Connor PG, Fiellin DA. 2000. Pharmacologic treatment of heroin-dependent patients. Ann. Intern. Med. 133(1):40-54
79. O'Connor PG, Kosten TR. 1998. Rapid and ultrarapid opioid detoxification techniques. JAMA 279(3):229-34
80. Off. Natl. Drug Control Policy. 1999. National Drug Control Strategy. Washington, DC: Gov. Print. Off. 138 pp.
81. Off. Natl. Drug Control Policy. 2000. National Drug Control Strategy. Washington, DC: Gov. Print. Off. 153 pp.
82. Off. Natl. Drug Control Policy. 1999. Opioid Agonist Treatment. Washington, DC: Off. Natl. Drug Control Policy
83. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. 1992. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch. Gen. Psychiatry 49(11):881-87
84. Parrino MW. 1998. The tornado of change. J. Maint. Addict. 1(3):71-80
85. Perneger TV, Giner F, del Rio M, Mino A. 1998. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. Br. Med. J. 317:13-18
86. Petty MM. 2000. A comprehensive guide for the application of contingency management procedures in standard clinic settings. Drug Alcohol Depend. 58:9-25
87. Petry NM, Martin B, Cooney JL, Kranzler HR. 2000. Give them prizes and they will come: contingency management for the treatment of alcohol dependence. J. Consult. Clin. Psychol. 68:250-57
88. Project MATCH Res. Group. 1998. Matching alcoholism treatments to client heterogeneity: Project MATCH three-year drinking outcomes. Alcohol. Clin. Exp. Res. 22(6):1300-11
89. Rajkumar AS, French MT 1997. Drug abuse, crime costs, and the economic benefits of treatment. J. Quant. Criminol. 13:291-323
90. Rawson RA, Hasson AL, Huber AM, McCann MJ, Ling W. 1998. A 3-year progress report on the implementation of LAAM in the United States. Addiction 93:533-40
91. Rettig RA, Yarmolinsky A, ed. 1995. Federal Regulation of Methadone Treatment. Washington, DC: Natl. Acad.
92. Reuter P. 2000. Are calculations of the economic costs of drug abuse either possible or useful? Addiction. In press
93. Roll J, Higgins ST, Badger GJ. 1996. An experimental comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar. J. App. Behav. Anal. 29:495-505
94. SAMHSA. 1997. Drug Abuse Warning Network Series: Year-End Preliminary Estimates From the 1996 Drug Abuse Warning Network. Rockville, MD: Dep. Health Hum. Serv., Subst. Abuse Ment. Health Serv. Admin.
95. SAMHSA. 1999. National Household Survey on Drug Abuse: Main Findings 1997. Rockville, MD: Dep. Health Hum. Serv., Subst. Abuse Ment. Health Serv. Admin.
96. Senay EC, Barthwell AG, Marks R, Bokos P, Gillman D, White R. 1993. Medical maintenance: a pilot study. J. Addict. Dis. 12(4):59-76
97. Shaner A, Roberts LJ, Eckman TA, Tucker DE, Tsuang JW, et al. 1997. Monetary reinforcement of abstinence from cocaine among mentally ill patients with cocaine dependence. Psychiatr. Serv. 48:807-10
98. Shephard D, Larson MJ, Hoffman N. 1999. Cost-effectiveness of substance abuse services. Addict. Disord. 22(2):385-99
99. Shephard D, Larson MJ, Hoffman N. 2000. Cost-effectiveness of substance abuse services: implications for public policy. Psychol. Clin. N. Am. In press
100. Silverman K, Higgins ST, Brooner RK, Montoya ID. 1996. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch. Gen. Psychiatry 53(5):409-15
101. Simpson DD, Joe GW, Brown BS. 1997. Treatment retention and follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol. Addict. Behav. 11(4):294-307
102. Sindelar JL, Jofre-Bonet M, French MT, McLellan AT. 2000. Cost effectiveness analysis of treatment for illicit drug dependence: paradoxes of multiple outcomes. PhD thesis. Yale Univ., New Haven, CT. In press
103. Sindelar JL, Manning WG. 1997. Cost-benefit and cost-benefit analysis: issues in the evaluation of the treatment of illicit drug abuse. In Treating Drug Abusers Effectively, ed. J Egertson, D Fox, A Leshner, pp. 187-222. London: Milbank/Blackwell
104. Stitzer ML, Bigelow GE, Liebson IA. 1980. Reducing drug use among methadone maintenance clients: contingent reinforcement for morphine free urines. Addict. Behav. 5:333-40
105. Stitzer ML, Bigelow, GE, Liebson IA, Hawthorne JW. 1982. Contingent reinforcement of benzodiazepine-free urines: evaluation of a drug abuse treatment intervention. J. App. Behav. Anal. 15:493-503
106. Strain E, Bigelow GE, Liebson IA, Stitzer ML. 1999. Moderate-vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 281:1000-5
107. Strain E, Stitzer M, Liebson I, Bigelow G. 1994. Comparison of buprenorphine and methadone in treatment of opiate dependence. Am. J. Psychol. 151:1025-31
108. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. 1993. Dose-response effects of methadone in the treatment of opioid dependence. Ann. Intern. Med. 119:23- 27
109. Tabbush V. 1986. The Effectiveness and Efficiency of Publicly Funded Drug Abuse Treatment and Prevention Programs in California: A Benefit-Cost Analysis. Berkeley: Univ. Calif. Press
110. Uchtenhagen A, Gutzwiller F, Dobler-Mikola A, Stephen T. 1997. "Programme for a Medical Prescription of Narcotics: a Synthesis of Results." Eur. Addiction Res. 3(4):160-63
111. Uniform Facility Data Set. 1998. Data on Substance Abuse Treatment Facilities. Drug and Alcohol Information Systems, Series S. Rockville, MD: Dep. Health Hum. Serv., Subst. Abuse Ment. Health Serv. Admin.
112. US Dep. Health Hum. Serv. 1993. State Methadone Treatment Guidelines. Rockville, MD: US Dep. Health Hum. Serv.
113. US Gen. Account. Off. 1997. Drug Courts: Overview of Growth, Character- istics, and Results. Washington, DC: US Gen. Account. Off.
114. Wexler H, DeLeon G, Thomas G, Kres- sel D. 2000. The Amity Prison TC eval- uation: reincarceration outcomes. Crim. Justice Behav. In press
115. Zaric G, Brandeau M, Barnett P. 2000. Methadone maintenance and HIV preven- tion: a cost-effectiveness analysis. Man- age. Sci. In press
116. Zarkin GA, French MT, Anderson DW, Bradley CJ. 1994. A conceptual frame- work for the economic evaluation of sub- stance abuse interventions. Eval. Prog. Plan. 17(4):409-18